HC Wainwright Has Optimistic Opinion of Precigen Q4 Earnings

Key Points

• HC Wainwright raised its Q4 2026 EPS estimate for Precigen to $0.11 from $0.06 and forecast earnings growth through 2027. It maintained a Buy rating and an $18 price target.
• Precigen reported quarterly EPS of $0.08, ahead of the $0.06 consensus cited in the article, and revenue of $74.15 million versus expectations of $71.55 million.
• Despite the upbeat results and analyst outlook, Precigen shares opened Friday at $4.22, down 16.4%; analyst consensus was Moderate Buy with an average price target of $13.50.

Precigen, Inc. (NASDAQ:PGEN - Free Report) - HC Wainwright upped their Q4 2026 EPS estimates for shares of Precigen in a research note issued to investors on Thursday, November 5th. HC Wainwright analyst S. Ramakanth now expects that the biotechnology company will post earnings per share of $0.11 for the quarter, up from their previous estimate of $0.06. HC Wainwright currently has a "Buy" rating and a $18.00 price target on the stock. The consensus estimate for Precigen's current full-year earnings is $0.23 per share. HC Wainwright also issued estimates for Precigen's Q1 2027 earnings at $0.13 EPS, Q2 2027 earnings at $0.15 EPS, Q3 2027 earnings at $0.17 EPS and Q4 2027 earnings at $0.19 EPS.

Several other brokerages have also issued reports on PGEN. B. Riley Financial assumed coverage on Precigen in a research note on Friday, September 25th. They issued a "buy" rating and a $12.00 price target on the stock. Citigroup restated a "market outperform" rating on shares of Precigen in a research report on Thursday. Wall Street Zen lowered Precigen from a "strong-buy" rating to a "buy" rating in a research note on Saturday, October 31st. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Precigen in a research note on Thursday, October 15th. Finally, Zacks Research cut Precigen from a "strong-buy" rating to a "hold" rating in a research report on Monday, October 5th. Four research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $13.50.

Precigen Stock Down 16.4%

NASDAQ PGEN opened at $4.22 on Friday. The business has a fifty day moving average price of $7.03 and a two-hundred day moving average price of $5.28. The company has a debt-to-equity ratio of 2.15, a current ratio of 4.58 and a quick ratio of 3.89. Precigen has a fifty-two week low of $3.04 and a fifty-two week high of $8.98. The stock has a market capitalization of $1.50 billion, a PE ratio of 42.20 and a beta of 1.01.

Precigen (NASDAQ:PGEN - Get Free Report) last announced its quarterly earnings data on Wednesday, November 4th. The biotechnology company reported $0.08 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.06 by $0.02. Precigen had a net margin of 15.55% and a return on equity of 86.42%. The business had revenue of $74.15 million for the quarter, compared to analysts' expectations of $71.55 million. During the same period last year, the firm posted ($1.06) earnings per share. The firm's quarterly revenue was up 2437.6% compared to the same quarter last year.

Insider Activity at Precigen

In related news, COO Rutul Shah sold 34,658 shares of the stock in a transaction that occurred on Friday, August 21st. The shares were sold at an average price of $7.50, for a total value of $259,935.00. Following the completion of the transaction, the chief operating officer owned 465,012 shares of the company's stock, valued at $3,487,590. This represents a 6.94% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Jeffrey Kindler sold 185,000 shares of the firm's stock in a transaction that occurred on Wednesday, August 26th. The shares were sold at an average price of $7.44, for a total transaction of $1,376,400.00. Following the completion of the sale, the director owned 17,100 shares in the company, valued at $127,224. This represents a 91.54% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 235,000 shares of company stock valued at $1,751,400. 41.40% of the stock is owned by insiders.

Institutional Investors Weigh In On Precigen

Hedge funds have recently modified their holdings of the company. Corient Private Wealth LP bought a new stake in shares of Precigen in the 2nd quarter valued at $1,908,000. The Manufacturers Life Insurance Company bought a new stake in shares of Precigen in the 2nd quarter worth $519,000. Bank of New York Mellon Corp bought a new stake in shares of Precigen in the 2nd quarter worth $2,705,000. Bank of America Corp DE bought a new position in shares of Precigen during the second quarter valued at about $10,536,000. Finally, Squarepoint Ops LLC increased its stake in Precigen by 462.8% in the 2nd quarter. Squarepoint Ops LLC now owns 353,272 shares of the biotechnology company's stock valued at $2,014,000 after buying an additional 290,505 shares during the last quarter. Institutional investors and hedge funds own 33.51% of the company's stock.

Key Precigen News

Here are the key news stories impacting Precigen this week:

• Positive Sentiment: HC Wainwright raised its EPS estimates for every quarter from Q4 2026 through Q4 2027, including its Q4 2027 forecast to $0.19 from $0.14. The firm reiterated its Buy rating and $18 price target, signaling increased confidence in expected earnings. Precigen stock coverage
• Positive Sentiment: Precigen reported PAPZIMEOS revenue of $72.9 million in Q3, up 37% sequentially, and said it generated positive cash flow a quarter ahead of guidance. The company also reported $35.8 million in net income and received FDA Platform Technology Designation for its AdenoVerse platform. Q3 results and business update
• Positive Sentiment: Citizens JMP raised its price target to $12 from $11 and maintained a Market Outperform rating, citing a higher PAPZIMEOS sales outlook after the quarterly update. Citizens JMP price-target coverage
• Neutral Sentiment: Q3 EPS was $0.08. That topped the $0.06 consensus cited by some coverage, but fell short of the $0.09 estimate cited by Zacks, making the earnings comparison mixed. Revenue of $74.15 million exceeded the $71.55 million estimate. Zacks Q3 earnings coverage

About Precigen

Precigen, Inc is a clinical-stage biotechnology company focused on developing gene and cell therapies for cancer and serious diseases. The company uses its proprietary UltraCAR-T, AdenoVerse, and other gene-engineering platforms to design potential treatments intended to improve the targeting, persistence, and manufacturing of therapeutic cells and genetic medicines.

Precigen's pipeline has included PRGN-2012, an investigational immunotherapy based on a gorilla adenovector for recurrent respiratory papillomatosis, as well as PRGN-2001, an investigational HPV-targeted immunotherapy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.